These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 15707400)

  • 1. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion.
    Pearl JP; Parris J; Hale DA; Hoffmann SC; Bernstein WB; McCoy KL; Swanson SJ; Mannon RB; Roederer M; Kirk AD
    Am J Transplant; 2005 Mar; 5(3):465-74. PubMed ID: 15707400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin.
    Kirk AD; Mannon RB; Kleiner DE; Swanson JS; Kampen RL; Cendales LK; Elster EA; Wakefield T; Chamberlain C; Hoffmann SC; Hale DA
    Transplantation; 2005 Oct; 80(8):1051-9. PubMed ID: 16278585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation.
    Sageshima J; Ciancio G; Guerra G; Gaynor JJ; Cova D; Zarak A; Chen L; Mattiazzi A; Kupin W; Roth D; Hanson L; Livingstone AS; Ruiz P; Burke GW
    Transpl Immunol; 2011 Sep; 25(2-3):104-11. PubMed ID: 21784152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment.
    Merino D; San Segundo D; Medina JM; Rodrigo E; Asensio E; Irure J; Fernández-Fresnedo G; Arias MA; López-Hoyos M
    Immunology; 2016 Jun; 148(2):206-15. PubMed ID: 26931075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation.
    Macedo C; Walters JT; Orkis EA; Isse K; Elinoff BD; Fedorek SP; McMichael JM; Chalasani G; Randhawa P; Demetris AJ; Zeevi A; Tan H; Shapiro R; Landsittel D; Lakkis FG; Metes D
    Transplantation; 2012 Apr; 93(8):813-21. PubMed ID: 22343334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab.
    Zeevi A; Husain S; Spichty KJ; Raza K; Woodcock JB; Zaldonis D; Carruth LM; Kowalski RJ; Britz JA; McCurry KR
    Am J Transplant; 2007 Feb; 7(2):471-5. PubMed ID: 17283491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H.
    Bloom DD; Chang Z; Fechner JH; Dar W; Polster SP; Pascual J; Turka LA; Knechtle SJ
    Am J Transplant; 2008 Apr; 8(4):793-802. PubMed ID: 18261176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H).
    Gallon L; Gagliardini E; Benigni A; Kaufman D; Waheed A; Noris M; Remuzzi G
    Clin J Am Soc Nephrol; 2006 May; 1(3):539-45. PubMed ID: 17699257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune profile of pediatric renal transplant recipients following alemtuzumab induction.
    De Serres SA; Mfarrej BG; Magee CN; Benitez F; Ashoor I; Sayegh MH; Harmon WE; Najafian N
    J Am Soc Nephrol; 2012 Jan; 23(1):174-82. PubMed ID: 22052056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression.
    Chen CC; Koenig A; Saison C; Dahdal S; Rigault G; Barba T; Taillardet M; Chartoire D; Ovize M; Morelon E; Defrance T; Thaunat O
    Front Immunol; 2018; 9():275. PubMed ID: 29515582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
    Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
    J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine.
    Morelon E; Lefrançois N; Besson C; Prévautel J; Brunet M; Touraine JL; Badet L; Touraine-Moulin F; Thaunat O; Malcus C
    Transpl Immunol; 2010 May; 23(1-2):53-8. PubMed ID: 20406686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro.
    Podestà MA; Binder C; Sellberg F; DeWolf S; Shonts B; Ho SH; Obradovic A; Waffarn E; Danzl N; Berglund D; Sykes M
    Am J Transplant; 2020 Jan; 20(1):88-100. PubMed ID: 31319439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.
    Trzonkowski P; Zilvetti M; Chapman S; Wieckiewicz J; Sutherland A; Friend P; Wood KJ
    Am J Transplant; 2008 Feb; 8(2):338-47. PubMed ID: 18211507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys.
    Marco MR; Dons EM; van der Windt DJ; Bhama JK; Lu LT; Zahorchak AF; Lakkis FG; Cooper DK; Ezzelarab MB; Thomson AW
    Transpl Immunol; 2013 Dec; 29(1-4):88-98. PubMed ID: 24120957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The number of circulating recent thymic emigrants is severely reduced 1 year after a single dose of alemtuzumab in renal transplant recipients.
    Scarsi M; Bossini N; Malacarne F; Valerio F; Sandrini S; Airò P
    Transpl Int; 2010 Aug; 23(8):786-95. PubMed ID: 20136785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys.
    Van Der Windt DJ; Smetanka C; Macedo C; He J; Lakomy R; Bottino R; Ekser B; Echeverri GJ; Metes D; Ijzermans JNM; Trucco M; Cooper DKC; Lakkis FG
    Am J Transplant; 2010 Apr; 10(4):773-783. PubMed ID: 20420638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients.
    Hoerning A; Köhler S; Jun C; Lu J; Fu J; Tebbe B; Dolff S; Feldkamp T; Kribben A; Hoyer PF; Witzke O
    Clin Exp Immunol; 2012 May; 168(2):251-9. PubMed ID: 22471287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
    Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB
    PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.